Lansigan, Frederick

Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma

Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J., Fanning, S., Kolibaba, K. S., Reynolds, C. M., Nowakowski, G. S., Gharibo, M., et al. (2021) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 14

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Ghosh, N., Lamanna, N., Eyre, T. A., Coombs, C. C., Manzoor, B. S., Brown, J. R., Tuncer, H. H., Ujjani, C. S., Leslie, L. A., Roeker, L. E., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 6